Colorectal cancer in inflammatory bowel disease: review of the evidence

Keller, Deborah S.; Windsor, Alistair; Cohen, Richard; Chand, Manish

doi:10.1007/s10151-019-1926-2

Cited by 185 publications

(138 citation statements)

References 98 publications

(103 reference statements)

Supporting

Mentioning

133

Contrasting

Unclassified

Order By: Relevance

“…However, many different conditions, including rheumatoid arthritis, have been inconsistently associated with breast cancer risk and do not support a strong association between chronic inflammatory conditions and breast cancer risk. The inconsistent evidence between medical conditions related to inflammation and breast cancer risk contrasts with other cancers, such as colorectal cancer, which have a much more consistent relationship with several chronic inflammatory [48]. The inconsistent evidence for breast cancer may be due to the timing of when inflammatory conditions were measured with respect to different windows of susceptibility for breast cancer.…”

Section: Medical Conditions Related To Chronic Inflammation and Breasmentioning

confidence: 97%

Inflammatory Biomarkers and Breast Cancer Risk: A Systematic Review of the Evidence and Future Potential for Intervention Research

Kehm

McDonald

Fenton

et al. 2020

IJERPH

View full text Add to dashboard Cite

Measuring systemic chronic inflammatory markers in the blood may be one way of understanding the role of inflammation in breast cancer risk, and might provide an intermediate outcome marker in prevention studies. Here, we present the results of a systematic review of prospective epidemiologic studies that examined associations between systemic inflammatory biomarkers measured in blood and breast cancer risk. From 1 January 2014 to 20 April 2020, we identified 18 unique studies (from 16 publications) that examined the association of systemic inflammatory biomarkers measured in blood with breast cancer risk using prospectively collected epidemiologic data. Only one marker, C-reactive protein, was studied extensively (measured in 13 of the 16 publications), and had some evidence of a positive association with breast cancer risk. Evidence associating other inflammatory biomarkers and more comprehensive panels of markers with the development of breast cancer is limited. Future prospective evidence from expanded panels of systemic blood inflammatory biomarkers is needed to establish strong and independent links with breast cancer risk, along with mechanistic studies to understand inflammatory pathways and demonstrate how breast tissue responds to chronic inflammation. This knowledge could ultimately support the development and evaluation of mechanistically driven interventions to reduce inflammation and prevent breast cancer.

show abstract

Section: Medical Conditions Related To Chronic Inflammation and Breasmentioning

confidence: 97%

Inflammatory Biomarkers and Breast Cancer Risk: A Systematic Review of the Evidence and Future Potential for Intervention Research

Kehm

McDonald

Fenton

et al. 2020

IJERPH

View full text Add to dashboard Cite

show abstract

“…They affect millions of people worldwide with increasing incidence ( Kaplan and Ng, 2017 ; Ng et al, 2018 ). IBDs result from the interaction between environmental, genetic, and epigenetic risk factors causing an excessive immune response in the mucosa leading to uncontrolled inflammation, and represent, in turn, a risk factor for the development of colorectal cancer ( Keller et al, 2019 ). Recent evidence suggests that the imbalance of the gut microbiota ecosystem, also known as gut dysbiosis, is linked to the initiation and progression of IBDs ( De Musis et al, 2020 ).…”

Section: Introductionmentioning

confidence: 99%

Fish Oil, Cannabidiol and the Gut Microbiota: An Investigation in a Murine Model of Colitis

Silvestri

Pagano

Lacroix³

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

Inflammatory bowel disorders can be associated with alterations in gut microbiota (dysbiosis) and behavioral disturbances. In experimental colitis, administration of fish oil (FO) or cannabinoids, such as cannabidiol (CBD), reduce inflammation. We investigated the effect of combined FO/CBD administration on inflammation and dysbiosis in the dextran sulphate sodium (DSS) model of mouse colitis, which also causes behavioral disturbances. Colitis was induced in CD1 mice by 4% w/v DSS in drinking water for five consecutive days followed by normal drinking water. FO (20–75 mg/mouse) was administered once a day starting two days after DSS, whereas CBD (0.3–30 mg/kg), alone or after FO administration, was administered once a day starting 3 days after DSS, until day 8 (d8) or day 14 (d14). Inflammation was assessed at d8 and d14 (resolution phase; RP) by measuring the Disease Activity Index (DAI) score, change in body weight, colon weight/length ratio, myeloperoxidase activity and colonic interleukin (IL)-1β (IL-1β), IL-10, and IL-6 concentrations. Intestinal permeability was measured with the fluorescein isothiocyanate-dextran. Behavioral tests (novel object recognition (NOR) and light/dark box test) were performed at d8. Fecal microbiota composition was determined by ribosomal 16S DNA sequencing of faecal pellets at d8 and d14. DSS-induced inflammation was stronger at d8 and accompanied by anxiety-like behavior and impaired recognition memory. FO (35, 50, 75 mg/mouse) alone reduced inflammation at d8, whereas CBD alone produced no effect at any of the doses tested; however, when CBD (3, 10 mg/kg) was co-administered with FO (75 mg/mouse) inflammation was attenuated. FO (20 mg/mouse) and CBD (1 mg/kg) were ineffective when given alone, but when co-administered reduced all inflammatory markers and the increased intestinal permeability at both d8 and d14, but not the behavioral impairments. FO, CBD, and their combination affected gut bacteria taxa that were not affected by DSS per se . Akkermansia muciniphila , a species suggested to afford anti-inflammatory action in colitis, was increased by DSS only at d14, but its levels were significantly elevated by all treatments at d8. FO and CBD co-administered at per se ineffective doses reduce colon inflammation, in a manner potentially strengthened by their independent elevation of Akkermansia muciniphila .

show abstract

“…The etiologies for UC are unclear, however, UC development and acute UC exacerbation have been associated with both physical and mental stress (9)(10)(11). Colorectal epithelium in UC patients with long disease duration has an increased risk of developing CRC, and IBDrelated CRC is responsible for 10-15% of the annual deaths in IBD patients (12). It is therefore of high importance to detect malignancy from UC at an earlier stage of the disease (13)(14)(15).…”

mentioning

confidence: 99%

Hypermethylation of Corticotropin Releasing Hormone Receptor-2 Gene in Ulcerative Colitis Associated Colorectal Cancer

Kobayashi¹,

Matsubara²,

Nakachi³

et al. 2019

In Vivo

View full text Add to dashboard Cite

Background/Aim: The difficulty of early diagnosis of colitis associated colorectal cancer (CACRC) due to colonic mucosal changes in long-standing ulcerative colitis (UC) patients is often experienced in daily clinical practice. Noninvasive objective monitoring for cancer development is advantageous for optimizing treatment strategies in UC patients. We aimed to examine the epigenetic alterations occurring in CACRC, focusing on DNA hypermethylation of CpG islands. Materials and Methods: The level of DNA methylation in CpG cites was compared between CACRC and the counterpart nontumorous mucosa using Infinium HumanMethylation 450K BeadChip. Results: Our subjects included 3 males and 3 females (median age, 49.5 years). The 450K CpG site DNA methylation microarray revealed that the difference in β value (level of hypermethylation) was the highest for corcicotropin releasing hormone receptor 2 (CRHR2) between CACRC and counterpart non-tumorous mucosa. Conclusion: Detection of hypermethylation of CRHR2 may be promising for cancer screening in UC patients.

show abstract

Colorectal cancer in inflammatory bowel disease: review of the evidence

Cited by 185 publications

References 98 publications

Inflammatory Biomarkers and Breast Cancer Risk: A Systematic Review of the Evidence and Future Potential for Intervention Research

Inflammatory Biomarkers and Breast Cancer Risk: A Systematic Review of the Evidence and Future Potential for Intervention Research

Fish Oil, Cannabidiol and the Gut Microbiota: An Investigation in a Murine Model of Colitis

Hypermethylation of Corticotropin Releasing Hormone Receptor-2 Gene in Ulcerative Colitis Associated Colorectal Cancer

Contact Info

Product

Resources

About